Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules

February 3, 2026

31 min episode · 2 min read

Simone Fishburne,Selena Koch,Lauren Martz

Episode

31 min

Read time

2 min

AI-Generated Summary

Published Mar 15, 2026

Key Takeaways

✓Lp(a) Phase 3 Benchmark: Ionis and Novartis's HORIZON trial of pelacarsen will deliver the first cardiovascular outcomes data testing whether Lp(a) reduction translates to clinical benefit. Affecting up to 30% of cardiovascular disease patients, this readout will influence development decisions across three competing phase 3 programs in different modalities targeting the same genetic risk factor.
✓RNAi Pipeline Breadth: Ten phase 3 trials across RNAi and antisense therapies are expected to read out in 2026, spanning IgA nephropathy, Angelman syndrome, DMD exon skipping, myotonic dystrophy type 1, and FSHD. Investors tracking this space should monitor Novartis, Ionis, Arrowhead, Wave, Alnylam, Biogen, and Avidity as the primary companies with late-stage catalysts.
✓IgA Nephropathy Regulatory Template: Five drugs received approval for IgA nephropathy in five years after the 2021 precedent of using proteinuria reduction as a surrogate endpoint. This pathway is now enabling regulatory submissions for at least three additional renal diseases without approved therapies, including APOL1-mediated kidney disease, FSGS, and membranous nephropathy, all with 2026 catalysts.
✓China Orphan Drug Exclusivity: China's new regulation, effective May 15, 2026, grants seven years of market exclusivity for orphan drugs plus a potential two additional years for pediatric indications. Key uncertainties remain: China lacks a formal rare disease definition beyond its 207-disease catalog, and whether pediatric exclusivity stacks onto or is included within the seven-year term is unresolved.
✓UK as Clinical Trial Destination: MHRA reduced clinical startup time from 250 days back toward 150 days under CEO Lawrence Tallon, and is building incentives specifically for ultra-orphan drug development. The UK's genomic data infrastructure and integrated HTA-reimbursement pathway position it as an emerging early-phase trial hub, particularly for genetic medicines where FDA safety margin requirements create friction.

What It Covers

BioCentury This Week episode 348 covers the second installment of 2026 biotech catalysts, focusing on RNAi and antisense therapies across cardiovascular, neuromuscular, and renal indications, plus analysis of China's first orphan drug exclusivity law granting seven years of market protection, effective May 15, 2026.

Key Questions Answered

•Lp(a) Phase 3 Benchmark: Ionis and Novartis's HORIZON trial of pelacarsen will deliver the first cardiovascular outcomes data testing whether Lp(a) reduction translates to clinical benefit. Affecting up to 30% of cardiovascular disease patients, this readout will influence development decisions across three competing phase 3 programs in different modalities targeting the same genetic risk factor.
•RNAi Pipeline Breadth: Ten phase 3 trials across RNAi and antisense therapies are expected to read out in 2026, spanning IgA nephropathy, Angelman syndrome, DMD exon skipping, myotonic dystrophy type 1, and FSHD. Investors tracking this space should monitor Novartis, Ionis, Arrowhead, Wave, Alnylam, Biogen, and Avidity as the primary companies with late-stage catalysts.
•IgA Nephropathy Regulatory Template: Five drugs received approval for IgA nephropathy in five years after the 2021 precedent of using proteinuria reduction as a surrogate endpoint. This pathway is now enabling regulatory submissions for at least three additional renal diseases without approved therapies, including APOL1-mediated kidney disease, FSGS, and membranous nephropathy, all with 2026 catalysts.
•China Orphan Drug Exclusivity: China's new regulation, effective May 15, 2026, grants seven years of market exclusivity for orphan drugs plus a potential two additional years for pediatric indications. Key uncertainties remain: China lacks a formal rare disease definition beyond its 207-disease catalog, and whether pediatric exclusivity stacks onto or is included within the seven-year term is unresolved.
•UK as Clinical Trial Destination: MHRA reduced clinical startup time from 250 days back toward 150 days under CEO Lawrence Tallon, and is building incentives specifically for ultra-orphan drug development. The UK's genomic data infrastructure and integrated HTA-reimbursement pathway position it as an emerging early-phase trial hub, particularly for genetic medicines where FDA safety margin requirements create friction.

Notable Moment

A Cambridge Bioscience CEO noted that China has historically been an afterthought for rare disease drug development and sales. The new exclusivity law targets changing that, particularly for diseases with patient populations above 10,000, which he described as the medium-rare range of orphan indications.

Know someone who'd find this useful?